RESMED INC (RMD) Insider Transactions
Over the last 12 months, 14 RESMED INC (RMD) insiders filed 114 SEC Form 4 transactions — $0 in open-market purchases ( 0 distinct buyers) and $29.2M in open-market sales. 9% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $29.2MOpen-market sells (1y)
- 14Distinct insiders
- 114Transactions filed
- 9%Under Rule 10b5-1 plan
- 2026-06-08Latest filing
Recent Form 4 Filings Most recent 50 of 114 (1-year window)
Each row is a single Form 4 filing event for RMD, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Farrell Michael J. | Chairman and CEO | Exercise 10b5-1 | M | $730.4K | 4,991 | $146.34 |
| 2026-06-08 | Farrell Michael J. | Chairman and CEO | Exercise | M | $0 | 4,991 | $0.00 |
| 2026-06-08 | Farrell Michael J. | Chairman and CEO | Sell 10b5-1 | S | $968.1K | 4,991 | $193.96 |
| 2026-06-01 | Rider Michael J | Global General Counsel | Other | F | $51.2K | 269 | $190.57 |
| 2026-05-07 | Farrell Michael J. | Chairman and CEO | Exercise 10b5-1 | M | $730.4K | 4,991 | $146.34 |
| 2026-05-07 | Farrell Michael J. | Chairman and CEO | Exercise 10b5-1 | M | $0 | 4,991 | $0.00 |
| 2026-05-07 | Farrell Michael J. | Chairman and CEO | Sell 10b5-1 | S | $1.0M | 4,991 | $207.82 |
| 2026-04-07 | Farrell Michael J. | Chairman and CEO | Exercise 10b5-1 | M | $730.4K | 4,991 | $146.34 |
| 2026-04-07 | Farrell Michael J. | Chairman and CEO | Exercise 10b5-1 | M | $0 | 4,991 | $0.00 |
| 2026-04-07 | Farrell Michael J. | Chairman and CEO | Sell 10b5-1 | S | $1.1M | 4,991 | $225.50 |
| 2026-04-01 | Sandercock Brett | Chief Financial Officer | Sell 10b5-1 | S | $224.3K | 1,000 | $224.31 |
| 2026-04-01 | FARRELL PETER C | — | Sell 10b5-1 | S | $450.0K | 2,000 | $225.00 |
| 2026-03-09 | Farrell Michael J. | Chairman and CEO | Grant | — | $730.4K | 4,991 | $146.34 |
| 2026-03-09 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 4,991 | $0.00 |
| 2026-03-09 | Farrell Michael J. | Chairman and CEO | Sell | — | $1.3M | 4,991 | $251.03 |
| 2026-03-04 | FARRELL PETER C | — | Sell | — | $520.4K | 2,000 | $260.22 |
| 2026-03-02 | Sandercock Brett | Chief Financial Officer | Sell | — | $254.3K | 1,000 | $254.30 |
| 2026-02-09 | Farrell Michael J. | Chairman and CEO | Grant | — | $730.4K | 4,991 | $146.34 |
| 2026-02-09 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 4,991 | $0.00 |
| 2026-02-09 | Farrell Michael J. | Chairman and CEO | Sell | — | $1.4M | 4,991 | $273.78 |
| 2026-02-04 | FARRELL PETER C | — | Sell | — | $502.6K | 2,000 | $251.31 |
| 2026-02-04 | Rider Michael J | Global General Counsel | Sell | — | $13.0K | 50 | $260.00 |
| 2026-02-02 | Sandercock Brett | Chief Financial Officer | Sell | — | $257.0K | 1,000 | $257.03 |
| 2026-01-07 | Farrell Michael J. | Chairman and CEO | Grant | — | $730.4K | 4,991 | $146.34 |
| 2026-01-07 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 4,991 | $0.00 |
| 2026-01-07 | FARRELL PETER C | — | Sell | — | $497.7K | 2,000 | $248.83 |
| 2026-01-07 | Farrell Michael J. | Chairman and CEO | Sell | — | $1.2M | 4,991 | $248.46 |
| 2026-01-02 | Sandercock Brett | Chief Financial Officer | Sell | — | $241.8K | 1,000 | $241.75 |
| 2026-01-02 | Rider Michael J | Global General Counsel | Sell | — | $12.1K | 50 | $241.75 |
| 2025-12-08 | Farrell Michael J. | Chairman and CEO | Grant | — | $730.4K | 4,991 | $146.34 |
| 2025-12-08 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 4,991 | $0.00 |
| 2025-12-08 | Farrell Michael J. | Chairman and CEO | Sell | — | $1.3M | 4,991 | $251.41 |
| 2025-12-03 | FARRELL PETER C | — | Sell | — | $502.9K | 2,000 | $251.47 |
| 2025-12-01 | Rider Michael J | Global General Counsel | Sell | — | $12.2K | 50 | $244.16 |
| 2025-12-01 | Sandercock Brett | Chief Financial Officer | Sell | — | $244.2K | 1,000 | $244.16 |
| 2025-11-25 | De Witte Jan | — | Sell | — | $524.0K | 2,055 | $255.00 |
| 2025-11-24 | Farrell Michael J. | Chairman and CEO | Grant | — | $8.3M | 33,288 | $250.52 |
| 2025-11-24 | FARRELL PETER C | — | Grant | — | $333.4K | 1,331 | $250.52 |
| 2025-11-24 | Mowad-Nassar Nicole | — | Grant | — | $333.4K | 1,331 | $250.52 |
| 2025-11-20 | Leong Justin | Chief Product Officer | Grant | — | $0 | 1,848 | $0.00 |
| 2025-11-20 | Hernandez John | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | Mowad-Nassar Nicole | — | Grant | — | $0 | 536 | $0.00 |
| 2025-11-20 | Tan Desney | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | Gill Harjit | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | Drexler Karen | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | Burt Carol | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | TAYLOR RONALD R | — | Grant | — | $0 | 1,073 | $0.00 |
| 2025-11-20 | Sandercock Brett | Chief Financial Officer | Grant | — | $0 | 2,710 | $0.00 |
| 2025-11-20 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 13,551 | $0.00 |
| 2025-11-20 | Farrell Michael J. | Chairman and CEO | Grant | — | $0 | 7,297 | $0.00 |
Showing the most recent 50 of 114 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track RMD Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for RESMED INC?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of RESMED INC (RMD) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of RESMED INC (RMD) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.